CN103710368A - 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 - Google Patents
哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 Download PDFInfo
- Publication number
- CN103710368A CN103710368A CN201310746269.XA CN201310746269A CN103710368A CN 103710368 A CN103710368 A CN 103710368A CN 201310746269 A CN201310746269 A CN 201310746269A CN 103710368 A CN103710368 A CN 103710368A
- Authority
- CN
- China
- Prior art keywords
- restructuring
- cell
- cho
- human kallikrein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 109
- 230000014509 gene expression Effects 0.000 title claims abstract description 61
- 102000001399 Kallikrein Human genes 0.000 title claims abstract description 27
- 108060005987 Kallikrein Proteins 0.000 title claims abstract description 26
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 16
- 210000004962 mammalian cell Anatomy 0.000 title abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 52
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims abstract description 23
- 230000008569 process Effects 0.000 claims abstract description 16
- 241000700605 Viruses Species 0.000 claims abstract description 11
- 238000001514 detection method Methods 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
- 238000006206 glycosylation reaction Methods 0.000 claims description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 14
- 230000012447 hatching Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 230000003248 secreting effect Effects 0.000 claims description 10
- 230000013595 glycosylation Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 238000002203 pretreatment Methods 0.000 claims description 7
- 241000699802 Cricetulus griseus Species 0.000 claims description 6
- 230000004899 motility Effects 0.000 claims description 6
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 238000000703 high-speed centrifugation Methods 0.000 claims description 5
- 238000001742 protein purification Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000004114 suspension culture Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000005457 optimization Methods 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000746 purification Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 102000012479 Serine Proteases Human genes 0.000 abstract description 2
- 108010022999 Serine Proteases Proteins 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 238000011965 cell line development Methods 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000012362 drug development process Methods 0.000 abstract 1
- 238000002331 protein detection Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 76
- 108020004705 Codon Proteins 0.000 description 40
- 239000000243 solution Substances 0.000 description 26
- 230000009182 swimming Effects 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 235000015097 nutrients Nutrition 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 101710176219 Kallikrein-1 Proteins 0.000 description 6
- 102100038297 Kallikrein-1 Human genes 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 230000005284 excitation Effects 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 108010025252 Kassinin Proteins 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- 102000003827 Plasma Kallikrein Human genes 0.000 description 3
- 108090000113 Plasma Kallikrein Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 229940047431 recombinate Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 101710192597 Protein map Proteins 0.000 description 2
- 101000848000 Rattus norvegicus Serine protease 1 Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- -1 acyl sulphur amino acid Chemical group 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940039088 kininogenase Drugs 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100026678 Carboxypeptidase N catalytic chain Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000057032 Tissue Kallikreins Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108010004046 tissue prokallikrein Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
调控作用元件 | 优化前 | 优化后 |
Splice(GGTAAG) | 0 | 0 |
Splice(GGTGAT) | 1 | 0 |
PolyA(AATAAA) | 0 | 0 |
PolyA(AAAAAA) | 0 | 0 |
Destabilizing(ATTTA) | 1 | 0 |
PolyT(TTTTTT) | 0 | 0 |
PolyA(AAAAAAA) | 0 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310746269.XA CN103710368B (zh) | 2013-12-30 | 2013-12-30 | 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310746269.XA CN103710368B (zh) | 2013-12-30 | 2013-12-30 | 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103710368A true CN103710368A (zh) | 2014-04-09 |
CN103710368B CN103710368B (zh) | 2016-08-17 |
Family
ID=50403724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310746269.XA Active CN103710368B (zh) | 2013-12-30 | 2013-12-30 | 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103710368B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105987998A (zh) * | 2015-01-30 | 2016-10-05 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1elisa定量检测试剂盒 |
CN105985437A (zh) * | 2015-01-30 | 2016-10-05 | 江苏众红生物工程创药研究院有限公司 | 抗人组织激肽释放酶1抗体及其应用 |
CN108265065A (zh) * | 2016-12-31 | 2018-07-10 | 江苏众红生物工程创药研究院有限公司 | 一种重组黄花蒿1类变应原蛋白及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101255438A (zh) * | 2008-04-11 | 2008-09-03 | 深圳大学 | 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法 |
CN101967468A (zh) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | 一种重组人胰激肽原酶 |
-
2013
- 2013-12-30 CN CN201310746269.XA patent/CN103710368B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101967468A (zh) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | 一种重组人胰激肽原酶 |
CN101255438A (zh) * | 2008-04-11 | 2008-09-03 | 深圳大学 | 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法 |
Non-Patent Citations (3)
Title |
---|
SHIN-ICHIRO YASUDA ET AL.: "Isolation of Zn2+ as an Endogenous Agonist of GPR39 from Fetal Bovine Serum", 《JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION》, 31 December 2007 (2007-12-31) * |
X. WANG ET AL.: "Secretion of Annexin V from Cultured Cells Requires a Signal Peptide", 《PLACENTA》, 31 December 2001 (2001-12-31) * |
叶志彪: "园艺产品品质生化分析与检测", 《园艺产品品质分析》, 31 July 2011 (2011-07-31), pages 187 - 189 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105987998A (zh) * | 2015-01-30 | 2016-10-05 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1elisa定量检测试剂盒 |
CN105985437A (zh) * | 2015-01-30 | 2016-10-05 | 江苏众红生物工程创药研究院有限公司 | 抗人组织激肽释放酶1抗体及其应用 |
CN105987998B (zh) * | 2015-01-30 | 2017-12-29 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1elisa定量检测试剂盒 |
CN105985437B (zh) * | 2015-01-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 抗人组织激肽释放酶1抗体及其应用 |
CN108265065A (zh) * | 2016-12-31 | 2018-07-10 | 江苏众红生物工程创药研究院有限公司 | 一种重组黄花蒿1类变应原蛋白及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103710368B (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
van Velthoven et al. | Stem cell quiescence: dynamism, restraint, and cellular idling | |
Moreno-Lastres et al. | Mitochondrial complex I plays an essential role in human respirasome assembly | |
Zanivan et al. | SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers | |
Küttner et al. | Loss of collagen VII is associated with reduced transglutaminase 2 abundance and activity | |
Ernoult et al. | A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation | |
EA200970263A1 (ru) | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков | |
Vu et al. | Scaffold-free 3D cell culture of primary skin fibroblasts induces profound changes of the matrisome | |
CN103897035A (zh) | 用于早期糖尿病诊断的多肽标志物 | |
CN103710368A (zh) | 哺乳动物细胞表达的人激肽释放酶和编码基因及其应用 | |
Ishihara et al. | Discovery of novel differentiation markers in the early stage of chondrogenesis by glycoform-focused reverse proteomics and genomics | |
Hookway et al. | Phenotypic variation between stromal cells differentially impacts engineered cardiac tissue function | |
CN113322230A (zh) | 一种牙髓干细胞外泌体及其制备方法和应用 | |
CN103710367B (zh) | 一种重组人激肽释放酶1及其编码基因和制备方法 | |
CN102023212B (zh) | 一种流感病毒神经氨酸酶抗体的快速检测方法 | |
CN106929496A (zh) | 一种药用级重组人激肽原酶产业化生产方法 | |
CN101736009B (zh) | 一种高密度发酵生产人白细胞介素6的方法 | |
CN106636108A (zh) | 一种特异性结合gpc3的核酸适配体及其应用 | |
CN107899002B (zh) | 骨钙素在调节内皮祖细胞外泌体中的应用 | |
CN105400813A (zh) | 一种重组表达人谷氨酸脱羧酶的毕赤酵母基因工程菌 | |
CN105802989A (zh) | 毕赤酵母表达重组蛋白的载体、基因、方法及应用 | |
CN110161253B (zh) | 一种免疫活性肽的筛选方法 | |
CN104745613A (zh) | 一种人激肽释放酶及其编码基因和应用制备方法 | |
CN103937829A (zh) | 人细胞色素p450 3a5酶及nadph-细胞色素p450氧化还原酶共表达体系 | |
Wu et al. | A comparative peptidomic characterization of cultured skeletal muscle tissues derived from db/db mice | |
CN101870735B (zh) | 一种新型高糖基化促红细胞生成素免疫融合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Patentee after: ZonHon Biopharma Institute Inc. Patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Patentee before: ZonHon Biopharma Institute Inc. Patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Co-patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190509 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |